T1	DISO 67 87	inmunidad debilitada
T2	DISO 90 113	infección por influenza
T3	DISO 115 120	gripe
#1	AnnotatorNotes T3	C0021400; Influenza; Disease or Syndrome
T4	CHEM 144 166	medicamento en estudio
#2	AnnotatorNotes T4	C0013230; Investigational New Drugs; Pharmacologic Substance
T5	CHEM 168 175	Tamiflu
#3	AnnotatorNotes T5	C0876173; Tamiflu; Organic Chemical · Pharmacologic Substance
T6	DISO 213 222	influenza
#4	AnnotatorNotes T6	C0021400; Influenza; Disease or Syndrome
T7	DISO 224 229	gripe
#5	AnnotatorNotes T7	C0021400; Influenza; Disease or Syndrome
T8	PROC 253 324	ENSAYO ABIERTO, ALEATORIZADO, ADAPTATIVO, DE DOS GRUPOS Y MULTICÉNTRICO
T9	PROC 330 377	EVALUAR LA FARMACOCINÉTICA Y LA FARMACODINÁMICA
T10	DISO 458 477	INMUNOCOMPROMETIDOS
T11	CHEM 394 405	OSELTAMIVIR
#6	AnnotatorNotes T11	C0874161; oseltamivir; Organic Chemical · Pharmacologic Substance
T12	CHEM 407 414	TAMIFLU
#7	AnnotatorNotes T12	C0876173; Tamiflu; Organic Chemical · Pharmacologic Substance
T13	PROC 423 434	TRATAMIENTO
#8	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	DISO 441 446	GRIPE
#9	AnnotatorNotes T14	C0021400; Influenza; Disease or Syndrome
T15	DISO 524 542	INFECCIÓN DE GRIPE
T16	DISO 1090 1093	ILI
#10	AnnotatorNotes T16	C0521839; Influenza-like illness; Disease or Syndrome
T17	DISO 605 625	inmunidad debilitada
T18	DISO 628 666	infección por el virus de la influenza
T19	DISO 668 673	gripe
#11	AnnotatorNotes T19	C0021400; Influenza; Disease or Syndrome
T20	PROC 701 712	Tratamiento
#12	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	DISO 719 724	gripe
#13	AnnotatorNotes T21	C0021400; Influenza; Disease or Syndrome
T22	PROC 834 872	Test de diagnóstico rápido de la gripe
T23	PROC 874 878	RIDT
#14	AnnotatorNotes T23	C4324569; Rapid influenza diagnostic test; Laboratory Procedure
T24	DISO 867 872	gripe
#15	AnnotatorNotes T24	C0021400; Influenza; Disease or Syndrome
T25	PROC 881 916	reacción en cadena de la polimerasa
#16	AnnotatorNotes T25	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T26	DISO 968 987	Inmunocomprometidos
T27	PROC 925 941	cultivo de virus
#17	AnnotatorNotes T27	C0200955; Viral culture procedure; Laboratory Procedure
T28	DISO 960 965	gripe
#18	AnnotatorNotes T28	C0021400; Influenza; Disease or Syndrome
T29	DISO 990 996	Signos
#19	AnnotatorNotes T29	C0311392; Physical findings; Finding
T30	DISO 997 1005	síntomas
#20	AnnotatorNotes T30	C1457887; Symptoms; Sign or Symptom
T31	DISO 1009 1032	enfermedad pseudogripal
#21	AnnotatorNotes T31	C0521839; Influenza-like illness; Disease or Syndrome
T32	CHEM 1117 1139	medicamento en estudio
#22	AnnotatorNotes T32	C0013230; Investigational New Drugs; Pharmacologic Substance
T33	DISO 1189 1211	insuficiencia hepática
#23	AnnotatorNotes T33	C0085605; Liver Failure; Disease or Syndrome | C1306571; Hepatic Insufficiency; Pathologic Function
T34	LIVB 1259 1269	prematuros
#24	AnnotatorNotes T34	C4048294; Preterm Infant; Age Group
T35	DISO 1340 1359	insuficiencia renal
#25	AnnotatorNotes T35	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T36	DISO 1362 1369	Alergia
#26	AnnotatorNotes T36	C1527304; Allergic Reaction; Pathologic Function
T37	CHEM 1373 1384	oseltamivir
#27	AnnotatorNotes T37	C0874161; oseltamivir; Organic Chemical · Pharmacologic Substance
T38	CHEM 1393 1404	excipientes
#28	AnnotatorNotes T38	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T39	DISO 1407 1445	Intolerancia a la fructosa hereditaria
#29	AnnotatorNotes T39	C0016751; Hereditary fructose intolerance syndrome; Disease or Syndrome
T40	CHEM 1546 1557	laninamivir
#30	AnnotatorNotes T40	C2931958; laninamivir; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T41	PROC 1463 1484	tratamiento antiviral
#31	AnnotatorNotes T41	C2363964; Antiviral treatment; Therapeutic or Preventive Procedure
T42	DISO 1495 1500	gripe
#32	AnnotatorNotes T42	C0021400; Influenza; Disease or Syndrome
T43	CHEM 1508 1518	amantadina
#33	AnnotatorNotes T43	C0002403; amantadine; Organic Chemical · Pharmacologic Substance
T44	CHEM 1520 1531	rimantadina
#34	AnnotatorNotes T44	C0035629; rimantadine; Organic Chemical · Pharmacologic Substance
T45	CHEM 1533 1544	oseltamivir
#35	AnnotatorNotes T45	C0874161; oseltamivir; Organic Chemical · Pharmacologic Substance
T46	CHEM 1570 1579	zanamivir
#36	AnnotatorNotes T46	C0216660; zanamivir; Organic Chemical · Pharmacologic Substance
T47	CHEM 1582 1592	ribavirina
#37	AnnotatorNotes T47	C0035525; ribavirin; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T48	PROC 1596 1607	tratamiento
#38	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	PROC 1649 1663	aleatorización
#39	AnnotatorNotes T49	C0034656; Randomization; Research Activity
T50	DISO 750 769	inmunocomprometidos
T51	CHEM 906 916	polimerasa
#40	AnnotatorNotes T51	C1335439; Polymerase; Amino Acid, Peptide, or Protein · Enzyme
T52	PROC 918 921	PCR
#41	AnnotatorNotes T52	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T53	ANAT 1203 1211	hepática
#42	AnnotatorNotes T53	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T54	ANAT 1354 1359	renal
#43	AnnotatorNotes T54	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T55	CHEM 1425 1433	fructosa
#44	AnnotatorNotes T55	C0016745; fructose; Organic Chemical · Pharmacologic Substance
T56	CHEM 1475 1484	antiviral
#45	AnnotatorNotes T56	C0003451; Antiviral Agents; Pharmacologic Substance
T57	CHEM 1612 1622	probenecid
#46	AnnotatorNotes T57	C0033209; probenecid; Organic Chemical · Pharmacologic Substance
T58	DISO 1034 1037	ILI
#47	AnnotatorNotes T58	C0521839; Influenza-like illness; Disease or Syndrome
T59	CHEM 1559 1568	peramivir
#48	AnnotatorNotes T59	C1675326; peramivir; Organic Chemical · Pharmacologic Substance
T60	Date 13 17	2012
T61	LIVB 57 62	niños
#49	AnnotatorNotes T61	C0008059; Child; Age Group
T62	PHYS 67 76	inmunidad
#50	AnnotatorNotes T62	C0020964; Immune response; Organ or Tissue Function | C0020965; Active immunity; Organ or Tissue Function
T64	PHYS 341 356	FARMACOCINÉTICA
#51	AnnotatorNotes T64	C0031327; Drug Kinetics; Physiologic Function
T65	Dose 381 390	DOS DOSIS
T66	LIVB 450 457	MENORES
#52	AnnotatorNotes T66	C0026193; Minor (person); Population Group
T68	Age 479 510	DE 2 SEMANAS A MENOS DE 13 AÑOS
T69	LIVB 577 582	Niños
#53	AnnotatorNotes T69	C0008059; Child; Age Group
T70	LIVB 585 600	adultos jóvenes
#54	AnnotatorNotes T70	C0238598; Young Adult; Age Group
T72	PHYS 605 614	inmunidad
#55	AnnotatorNotes T72	C0020964; Immune response; Organ or Tissue Function | C0020965; Active immunity; Organ or Tissue Function
T73	LIVB 645 666	virus de la influenza
#56	AnnotatorNotes T73	C0029341; Orthomyxoviridae; Virus
T74	LIVB 728 749	pacientes pediátricos
#57	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group + C0008059; Child; Age Group
T75	LIVB 798 821	Niños varones o hembras
#58	AnnotatorNotes T75	C0008059; Child; Age Group + C0870221; Boys; Age Group + C0870604; Female child; Age Group
T76	Age 823 831	<13 años
T77	LIVB 936 941	virus
#59	AnnotatorNotes T77	C0042776; Virus; Virus
T78	Duration 1041 1068	Menos de o igual a 96 horas
T79	CONC 1099 1112	primera dosis
T80	LIVB 1220 1225	Niños
#60	AnnotatorNotes T80	C0008059; Child; Age Group
T81	Age 1226 1236	<2 semanas
T82	PHYS 1289 1298	menstrual
#61	AnnotatorNotes T82	C0025344; Menstruation; Organism Function
T83	Age 1305 1316	<36 semanas
T84	Duration 1626 1635	2 semanas
T85	PHYS 194 206	recuperación
#62	AnnotatorNotes T85	C2004454; Recovery - healing process; Organism Function
T67	Date 1284 1298	post-menstrual
T71	PHYS 362 377	FARMACODINÁMICA
#63	AnnotatorNotes T71	C0851347; Pharmacodynamics; Biologic Function
A1	Population_data T66 Age
A2	Population_data T61 Age
A3	Population_data T69 Age
A4	Population_data T70 Age
A5	Population_data T74 Age
A6	Population_data T75 Age
A7	Population_data T80 Age
A8	Status T41 History_of
A9	Status T56 History_of
A10	Status T43 History_of
A11	Status T44 History_of
A12	Status T57 History_of
A13	Status T48 History_of
A14	Status T47 History_of
A15	Status T46 History_of
A16	Status T59 History_of
A17	Status T40 History_of
A18	Status T45 History_of
A19	Population_data T34 Age
A20	Status T36 History_of
A21	Status T39 History_of
R1	Experiences Arg1:T61 Arg2:T1	
R2	Overlap Arg1:T1 Arg2:T2	
R3	Experiences Arg1:T61 Arg2:T62	
R4	Experiences Arg1:T61 Arg2:T2	
R5	Experiences Arg1:T61 Arg2:T3	
R6	Experiences Arg1:T61 Arg2:T4	
R7	Experiences Arg1:T61 Arg2:T5	
R8	Experiences Arg1:T61 Arg2:T85	
R9	Experiences Arg1:T61 Arg2:T6	
R10	Experiences Arg1:T61 Arg2:T7	
R14	Before Arg1:T6 Arg2:T85	
R15	Before Arg1:T7 Arg2:T85	
R16	Before Arg1:T2 Arg2:T85	
R17	Before Arg1:T3 Arg2:T85	
#65	AnnotatorNotes T1	C0085393; Immunocompromised Host; Finding
#66	AnnotatorNotes T10	C0085393; Immunocompromised Host; Finding
R20	Has_Dose_or_Strength Arg1:T11 Arg2:T65	
R21	Has_Dose_or_Strength Arg1:T12 Arg2:T65	
R22	Used_for Arg1:T12 Arg2:T13	
R23	Used_for Arg1:T11 Arg2:T13	
R24	Experiences Arg1:T66 Arg2:T64	
R25	Experiences Arg1:T66 Arg2:T71	
R26	Experiences Arg1:T66 Arg2:T11	
R27	Experiences Arg1:T66 Arg2:T12	
R28	Experiences Arg1:T66 Arg2:T14	
R29	Experiences Arg1:T66 Arg2:T10	
R30	Experiences Arg1:T66 Arg2:T15	
R31	Overlap Arg1:T10 Arg2:T15	
R32	Overlap Arg1:T14 Arg2:T10	
R33	Has_Age Arg1:T66 Arg2:T68	
#67	AnnotatorNotes T17	C0085393; Immunocompromised Host; Finding
#68	AnnotatorNotes T50	C0085393; Immunocompromised Host; Finding
R34	Experiences Arg1:T69 Arg2:T17	
R35	Experiences Arg1:T69 Arg2:T72	
R36	Experiences Arg1:T69 Arg2:T18	
R37	Experiences Arg1:T69 Arg2:T19	
R38	Experiences Arg1:T70 Arg2:T17	
R39	Experiences Arg1:T70 Arg2:T18	
R40	Experiences Arg1:T70 Arg2:T19	
R41	Causes Arg1:T73 Arg2:T18	
R42	Causes Arg1:T73 Arg2:T19	
R45	Overlap Arg1:T17 Arg2:T18	
R46	Overlap Arg1:T17 Arg2:T19	
R47	Overlap Arg1:T21 Arg2:T50	
R48	Experiences Arg1:T74 Arg2:T20	
R49	Experiences Arg1:T74 Arg2:T21	
R50	Experiences Arg1:T74 Arg2:T50	
R51	Has_Age Arg1:T75 Arg2:T76	
R52	Causes Arg1:T31 Arg2:T30	
R53	Causes Arg1:T31 Arg2:T29	
R54	Causes Arg1:T58 Arg2:T30	
R55	Causes Arg1:T58 Arg2:T29	
R56	Before Arg1:T16 Arg2:T78	
R57	Has_Dose_or_Strength Arg1:T32 Arg2:T79	
R59	Before Arg1:T16 Arg2:T32	
R60	After Arg1:T32 Arg2:T78	
R58	Location_of Arg1:T53 Arg2:T33	
T86	Quantifier_or_Qualifier 1212 1217	grave
#69	AnnotatorNotes T86	C1547227; Severe - Severity of Illness Code; Intellectual Product
R61	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T86	
T87	CONC 1168 1185	Evidencia clínica
#70	AnnotatorNotes T87	C5554846; Clinical Evidence; Idea or Concept
R62	Has_Age Arg1:T34 Arg2:T83	
R63	Has_Age Arg1:T80 Arg2:T81	
T88	CONC 1319 1336	Evidencia clínica
#71	AnnotatorNotes T88	C5554846; Clinical Evidence; Idea or Concept
R64	Location_of Arg1:T54 Arg2:T35	
R65	Causes Arg1:T37 Arg2:T36	
R66	Causes Arg1:T38 Arg2:T36	
R67	Causes Arg1:T55 Arg2:T39	
R68	Used_for Arg1:T56 Arg2:T41	
R69	Used_for Arg1:T43 Arg2:T41	
R70	Used_for Arg1:T44 Arg2:T41	
R71	Used_for Arg1:T45 Arg2:T41	
R72	Used_for Arg1:T40 Arg2:T41	
R73	Used_for Arg1:T59 Arg2:T41	
R74	Used_for Arg1:T46 Arg2:T41	
R75	Used_for Arg1:T47 Arg2:T41	
R76	Used_for Arg1:T57 Arg2:T48	
R77	Before Arg1:T48 Arg2:T49	
R78	Overlap Arg1:T57 Arg2:T84	
R79	Before Arg1:T41 Arg2:T49	
R80	Overlap Arg1:T56 Arg2:T84	
R81	Overlap Arg1:T43 Arg2:T84	
R82	Overlap Arg1:T44 Arg2:T84	
R83	Overlap Arg1:T45 Arg2:T84	
R84	Overlap Arg1:T40 Arg2:T84	
R85	Overlap Arg1:T59 Arg2:T84	
R86	Overlap Arg1:T46 Arg2:T84	
R87	Overlap Arg1:T47 Arg2:T84	
R90	Causes Arg1:T77 Arg2:T28	
T89	Result_or_Value 942 951	positivos
#72	AnnotatorNotes T89	C1446409; Positive; Finding
R94	Has_Result_or_Value Arg1:T27 Arg2:T89	
R95	Causes Arg1:T77 Arg2:T89	
#73	AnnotatorNotes T26	C0085393; Immunocompromised Host; Finding
R11	Overlap Arg1:T1 Arg2:T3	
R12	Before Arg1:T1 Arg2:T85	
R13	Overlap Arg1:T1 Arg2:T6	
R18	Overlap Arg1:T1 Arg2:T7	
#64	AnnotatorNotes T2	C0021400; Influenza; Disease or Syndrome
#74	AnnotatorNotes T15	C0021400; Influenza; Disease or Syndrome
R19	Has_Result_or_Value Arg1:T22 Arg2:T89	
R43	Has_Result_or_Value Arg1:T25 Arg2:T89	
R44	Has_Result_or_Value Arg1:T23 Arg2:T89	
R88	Has_Result_or_Value Arg1:T52 Arg2:T89	
R89	Causes Arg1:T77 Arg2:T24	
#75	AnnotatorNotes T79	C5236155; Date of First Dose; Temporal Concept
#76	AnnotatorNotes R57	(?)
#77	AnnotatorNotes T9	C0201734; Pharmacokinetic study; Research Activity + C1709518; Pharmacodynamic Study; Research Activity
#78	AnnotatorNotes T18	C0851891; Influenza viral infections; Disease or Syndrome
#79	AnnotatorNotes T22	C4324569; Rapid influenza diagnostic test; Laboratory Procedure
A22	Experiencer T61 Patient
A23	Experiencer T66 Patient
A24	Experiencer T69 Patient
A25	Experiencer T70 Patient
A26	Experiencer T74 Patient
A27	Experiencer T75 Patient
A28	Experiencer T80 Patient
A29	Experiencer T34 Patient
A30	Assertion T34 Hypothetical
